872206-45-6

Basic information

• Product Name: 6-hydroxy-5-Methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one
• Synonyms: 6-hydroxy-5-Methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one;6-Hydroxy-5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one;5-Methyl-4-oxo-3,4-dihydropyrrolo[1,2-f][1,2,4]triazin-6-yl pivalate;6-hydroxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4(1H)-one;6-Hydroxy-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-one
• CAS NO: 872206-45-6
• Molecular Formula: C7H7N3O2
• Molecular Weight: 165.14938
• Mol File: 872206-45-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.61
• CAS DataBase Reference: 6-hydroxy-5-Methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-hydroxy-5-Methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one(872206-45-6)
• EPA Substance Registry System: 6-hydroxy-5-Methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one(872206-45-6)

Safety Data

• Hazardous Substances Data: 872206-45-6(Hazardous Substances Data)

Usage

General Description

6-hydroxy-5-Methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one is a chemical compound with the molecular formula C6H5N3O2. It is a heterocyclic compound containing both nitrogen and oxygen atoms in its structure. This chemical is a pyrrolopyrimidine derivative, which has potential applications in pharmaceutical research and drug development. The compound has been studied for its potential biological activities, including its anti-inflammatory and anti-cancer properties. Additionally, it may also have applications in the field of organic synthesis and material science due to its unique structure and reactivity. Further research on this compound could lead to the development of new pharmaceuticals and materials with important scientific and industrial applications.

Upstream product

• 872206-43-4 C₁₀H₁₃N₃O₂ 
• 621685-55-0 C₈H₇N₃O₂ 
• 621685-54-9 C₈H₉N₃O₂ 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 427878-70-4 ethyl 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 

Downstream Products

• 952490-01-6 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl pivalate 
• 872206-47-8 C₁₂H₁₅N₃O₃ 

Relevant articles and documents

Development of a continuous plug flow process for preparation of a key intermediate for brivanib alaninate

A thermal runaway potential was identified for the conversion of a tertiary alcohol to a hydroxypyrrolotriazine intermediate in the synthesis of brivanib alaninate. A continuous process was developed to mitigate the potential thermal runaway and allow for safer scale-up. This paper describes the hazard analysis, process development, reactor development, reaction engineering model development, and scale-up of the continuous process. The process includes three separate and stable feed streams that are mixed in distinct order using in-line static mixers. Heat exchangers are arranged and connected to facilitate a "plug flow" reactor scheme allowing sufficient residence time for reaction completion. The process has been scaled-up to the pilot plant and to manufacturing.

Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2

c-Met and VEGFR-2 have attracted interest as novel targets for treatment of various cancers. Aiming to develop potent dual c-Met and VEGFR-2 inhibitors, a series of pyrrolo[1,2-f][1,2,4]triazine derivatives were designed and synthesized. The majority of target compounds exhibited potent antiproliferative effect against c-Met addictive cancer cell lines with IC50 values ranged from 1.2 to 24.6 nM, especially 27a. In-depth studies demonstrated 27a has great selectivity to c-Met and VEGFR-2, and potent inhibitory activity against them (IC50 of 2.3 ± 0.1 nM and 5.0 ± 0.5 nM). Furthermore, it also showed the highest anticancer activity with IC50 of 0.71 ± 0.16 nM (better than the positive compound) against BaF3-TPR-Met and 37.4 ± 0.311 nM (comparable to the positive compound) against HUVEC-VEGFR2, consistent with that in c-Met sensitive tumor cell lines. Subsequently, physicochemical and pharmacokinetic characterization indicated 27a has favorable druggability and pharmacokinetic properties. Further docking studies suggested a common mode of interaction at the ATP-binding site of c-Met and VEGFR-2, also indicating that 27a was a potential candidate for cancer therapy deserving further study.

Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith

The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one ki